Differentiating carcinoid syndrome from other diseases: Difference between revisions
No edit summary |
No edit summary |
||
Line 21: | Line 21: | ||
| colspan="8" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="8" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
| | | | ||
! colspan=" | ! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | | colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
Line 37: | Line 37: | ||
! | ! | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! colspan=" | ! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
! | ! | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
Line 55: | Line 55: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 3 | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 3 | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal computed tomography (CT) | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdominal computed tomography (CT) | ||
!MRI | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |somatostatin receptor scintigraphy [SRS], or Octreoscan | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |somatostatin receptor scintigraphy [SRS], or Octreoscan | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metaiodobenzylguanidine (MIBG) scintigraphy | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metaiodobenzylguanidine (MIBG) scintigraphy | ||
Line 75: | Line 76: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 97: | Line 99: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 119: | Line 122: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 127: | Line 131: | ||
|- | |- | ||
|Malignant neoplasms of small intestine | |Malignant neoplasms of small intestine | ||
| | |||
| | | | ||
| | | | ||
Line 149: | Line 154: | ||
|- | |- | ||
|Benign cutaneous flushing | |Benign cutaneous flushing | ||
| | |||
| | | | ||
| | | | ||
Line 171: | Line 177: | ||
|- | |- | ||
|Recurrent idiopathic anaphylaxis | |Recurrent idiopathic anaphylaxis | ||
| | |||
| | | | ||
| | | | ||
Line 207: | Line 214: | ||
!Lab 3 | !Lab 3 | ||
!Imaging 1 | !Imaging 1 | ||
! | |||
!Imaging 2 | !Imaging 2 | ||
!Imaging 3 | !Imaging 3 | ||
Line 229: | Line 237: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 251: | Line 260: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 273: | Line 283: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 21:52, 6 February 2019
Carcinoid syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Differentiating carcinoid syndrome from other diseases On the Web |
American Roentgen Ray Society Images of Differentiating carcinoid syndrome from other diseases |
FDA on Differentiating carcinoid syndrome from other diseases |
CDC on Differentiating carcinoid syndrome from other diseases |
Differentiating carcinoid syndrome from other diseases in the news |
Blogs on Differentiating carcinoid syndrome from other diseases |
Risk calculators and risk factors for Differentiating carcinoid syndrome from other diseases |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Carcinoid syndrome must be differentiated from systemic mastocytosis, medullary thyroid carcinoma, irritable bowel syndrome, malignant neoplasms of the small intestine, benign cutaneous flushing, and recurrent idiopathic anaphylaxis.
Differentiating Carcinoid Syndrome from other Diseases
Carcinoid syndrome must be differentiated from:[1]
- Systemic mastocytosis
- Medullary thyroid carcinoma
- Irritable bowel syndrome
- Malignant neoplasms of the small intestine
- Benign cutaneous flushing
- Recurrent idiopathic anaphylaxis
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||||||||
Abdominal pain | Diarrhea | Flushing | Dyspnea | Palpitations | Wheezing | Telangiectasia | Hypotension | Lab 1 | Serum Chromogranin A (CgA) | Lab 3 | Abdominal computed tomography (CT) | MRI | somatostatin receptor scintigraphy [SRS], or Octreoscan | Metaiodobenzylguanidine (MIBG) scintigraphy |
| ||||||
Carcinoid Syndrome | Urinary 5-hydroxyindoleacetic acid (5-HIAA) | ||||||||||||||||||||
Irritable Bowel Syndrome | |||||||||||||||||||||
Systemic mastocytosis | |||||||||||||||||||||
Malignant neoplasms of small intestine | |||||||||||||||||||||
Benign cutaneous flushing | |||||||||||||||||||||
Recurrent idiopathic anaphylaxis | |||||||||||||||||||||
Diseases | Symptom 1 | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Lab 1 | Lab 2 | Lab 3 | Imaging 1 | Imaging 2 | Imaging 3 | Histopathology | Gold standard | Additional findings | ||||||
Crohn disease | |||||||||||||||||||||
Asthma | |||||||||||||||||||||
Differential Diagnosis 6 |
References
- ↑ Metcalfe DD (2000). "Differential diagnosis of the patient with unexplained flushing/anaphylaxis". Allergy Asthma Proc. 21 (1): 21–4. PMID 10748948.